Clinical trial
Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
NCT07917364 is registered in ClinicalTrials.gov with University of Applied Sciences in Nowy Targ as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
- Lead sponsor
- University of Applied Sciences in Nowy Targ
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 30, 2026
- Completion date
- March 31, 2027
- Enrollment
- 110 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Metabolic Syndrome Group (MetS)
Women aged 18-35 years meeting NCEP ATP III criteria for metabolic syndrome (at least three of five components: triglycerides greater than 150 mg/dL; HDL cholesterol below 50 mg/dL; blood pressure greater than 130/85 mmHg or antihypertensive treatment; fasting glucose greater than 100 mg/dL or previously diagnosed diabetes; waist circumference greater than 88 cm), with no other comorbidity requiring continuous pharmacotherapy. Target n=55.
-
Control Group (CON)
Healthy women aged 18-35 years not meeting NCEP ATP III criteria for metabolic syndrome, matched for age, not receiving continuous pharmacotherapy. Target n=55.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Serum asprosin concentration
Fasting serum asprosin concentration measured by enzyme-linked immunosorbent assay, compared between women with metabolic syndrome and healthy controls. Reported in ng/mL.
-
Expression of selected circulating microRNAs
Relative expression of six circulating microRNAs (miR-15a-5p, miR-197-3p, miR-23a-3p, miR-21-5p, miR-146a-5p, miR-223-3p) quantified in plasma by reverse-transcription quantitative PCR. Expression is normalized using ath-miR159a as an exogenous spike-in control and hsa-miR-186-5p as a reference. All six analytes are measured by the same method and reported in the same unit of measure, relative fold change, with results reported separately for each microRNA.
Similar trials
Same condition (Arachnodactyly) and phase, most recent start first.
+10 more trials See the condition page